Antithrombotic Strategies in Endovascular Interventions: Current Status and Future Directions

Mehdi H Shishehbor; Barry T Katzen

doi:10.1016/j.iccl.2013.06.005

Antithrombotic Strategies in Endovascular Interventions: Current Status and Future Directions

Interv Cardiol Clin. 2013 Oct;2(4):627-633. doi: 10.1016/j.iccl.2013.06.005. Epub 2013 Jul 25.

Authors

Mehdi H Shishehbor¹, Barry T Katzen²

Affiliations

¹ Endovascular Services, Heart & Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, J3-05, Cleveland, OH 44195, USA. Electronic address: shishem@ccf.org.
² Baptist Cardiac & Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176, USA.

PMID: 28582189
DOI: 10.1016/j.iccl.2013.06.005

Abstract

Despite increasing numbers of endovascular interventions to treat arterial and venous disease, scant level 1 evidence is available regarding the role of antithrombotic and antiplatelet therapy in patients undergoing these procedures. The current practice in this regard is heterogeneous and has mainly been driven by data from coronary artery disease and percutaneous coronary intervention. This article discusses the role of antithrombotic and antiplatelet agents for endovascular intervention.

Keywords: Antiplatelet agents; Antithrombotic therapy; EUCLID trial; Endovascular intervention; Peripheral artery disease.

Publication types

Review